Recon: CanSino moving COVID-19 vaccine into Phase II; Damages in BMS, Gilead patent case boosted to $1.2B

• CDC Director: 'Very Aggressive' Contact Tracing Needed For US To Return To Normal (NPR)
• The coming White House coronavirus clash (Politico)
• Three US local governments to adopt coronavirus contact tracing app: MIT (Reuters)
• Biogen sues life science supplier over ‘brazen’ Alzheimer’s knockoff (Boston Business Journal)
• Bristol-Myers Patent Win Over Gilead Grows to $1.2 Billion (Bloomberg) (Reuters)
• Gilead Rips Merck's New Bid To Restore $2.5B Patent Verdict (Law360-$)
• Data for Regeneron arthritis drug in coronavirus could come in weeks (STAT) (Reuters)
• A Perspective on the FDA’s COVID-19 Response (FDA)

• China's CanSino Bio advances COVID-19 vaccine into phase 2 on preliminary safety data (Fierce)
• Covid-19 drugs could be made for $1 per day, say academics (Financial Times) (Reuters)
• A New Front for Nationalism: The Global Battle Against a Virus (NYTimes)
• Sanofi will donate 100 million doses of hydroxychloroquine to 50 countries (Reuters)              
• India set to ship drug sought by Trump for coronavirus (Reuters) (Economic Times) (NPR)
• UK PM Johnson leaves intensive care, remains under observation (Reuters)
• Iceland’s ‘Test Everyone’ Goal Has Skeptics, but It May Be Working (Reuters)
• China imposes more checks on mask exports to ensure quality control (Reuters)
• South Korea reports recovered coronavirus patients testing positive again (Reuters)
• EU Finance Ministers Reach $590 Billion Coronavirus Rescue Deal (NPR)
• Malaysian firms led by world's top glove maker prioritise medical supplies (Reuters)
• Drones take Italians' temperature and issue fines (AFP)

• Searching for an effective Covid-19 treatment: promise and peril (STAT)
• At the Center of a Storm: The Search for a Proven Coronavirus Treatment (NYTimes)
• Oxford recruits 2,700 virus patients for fast-growing drugs trial (Financial Times)
• Novavax fast-tracks phase 1 testing of coronavirus vaccine (PMLive)
• How the CARES Act affects COVID-19 test pricing (Brookings)
• The Pandemic Will Cleave America in Two (The Atlantic)
• Coronavirus now leading cause of death in US (The Hill)
• It’s difficult to grasp the projected deaths from Covid-19. Here’s how they compare to other causes of death (STAT)
• HHS Rolls Out Initial $30 Billion for Hospitals From CARES Act (Bloomberg Law)
• Checkpoints, Curfews, Airlifts: Virus Rips Through Navajo Nation (NYTimes)
• Adapting cancer research to coronavirus (Politico)
• Doctors ‘keep an open mind’ about unproven coronavirus drug, but worry it could do more harm than good (STAT)
• Thousands of coronavirus tests are going unused in US labs (Nature)
• Hydroxychloroquine Abuse Up Since Trump First Mentioned Drug, US Poison Center Data Says (Forbes)
• Brazil minister resists calls for wider use of hydroxychloroquine (Reuters)
• Indian manufacturers set to double production of hydroxychloroquine to meet rising demand (Pharmabiz)
• Faulty N95 Masks Hamper Hospitals on Coronavirus Front Line (WSJ)
• BioCryst starts COVID-19 trial of broad-spectrum antiviral (Fierce)
• As fever checks become the norm in coronavirus era, demand for thermal cameras soars (Reuters)
• We Need True Positives, True Negatives: Doggett and DeLauro Press FDA for Data on the Accuracy of COVID-19 Tests (DeLauro)
• On Russian border, China scrambles to contain coronavirus influx (Reuters)
• China's Wuhan to keep testing residents as coronavirus lockdown eases (Reuters)
• Once the biggest outbreak outside of China, South Korean city reports zero new coronavirus cases (Reuters)
• California governor encouraged by drop in ICU placements (AP)
• 'You can't relax': Vigilance urged as New York sees signs of coronavirus progress (Reuters)
• Japan's coronavirus infections surpass 6,000 cases: NHK (Reuters)
• Tokyo seeks shop shutdowns, Kyoto warns tourists away as coronavirus threatens Japan economy (Reuters)
• Spain's coronavirus death toll curve flattening at last (Reuters)
• Number of French people in ICU for coronavirus falls for the first time (Reuters)
• Moscow, in U-turn, to assume all pneumonia patients may have coronavirus (Reuters)
• Early testing helps Canada's British Columbia fight coronavirus, cases elsewhere soar (Reuters)
• Georgia Resident Arrested for Selling Illegal Products Claiming to Protect Against Viruses (DOJ)
• Approval Tests and Standards for Air-Purifying Particulate Respirators (HHS)
• 'It Tortures Me That I'm Not There Helping.' Former FDA Commissioner Scott Gottlieb on the Fight Against COVID-19 (Time)

• How will the pandemic shape biotech in the months ahead? An industry analyst weighs in (STAT)
• States Can Use the Coronavirus Response to Go After Insulin Price Gougers (Slate)
• COVID-19 Trial Changes Are “Propulsive Force” For Digital Adoption (Pink Sheet-$)
• The Path Towards a Tailored Clinical Biosimilar Development (BioDrugs)
• Eye drug side effects are real, Novartis confirms in new warning (BioPharmaDive)
• Pharma operations: Creating the workforce of the future (McKinsey)
• Biopharma portfolio strategy in the era of cell and gene therapy (McKinsey)
• Arix cuts costs, changes leadership team to hunker down (Fierce)
• Digital Doublespeak: The Language Barrier When Tech Companies Meet Regulators (Pink Sheet-$)
• Nonresearch Pharmaceutical Industry Payments to Oncology Physician Editors (The Oncologist)
• Information Pertaining to Additional Safety Protections Regarding Use of Fecal Microbiota for Transplantation - Screening Donors for COVID-19 and Exposure to SARS-CoV-2 and Testing for SARS-CoV-2 (FDA)
• Temporary Policy Regarding Non-Standard PPE Practices for Sterile Compounding by Pharmacy Compounders not Registered as Outsourcing Facilities During the COVID-19 Public Health Emergency (FDA)
• Policy for the Temporary Use of Portable Cryogenic Containers Not in Compliance With 21 CFR 211.94(e)(1) For Oxygen and Nitrogen During the COVID-19 Public Health Emergency Guidance for Industry (FDA)

• Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis (Press)
• Astellas Announces Acceptance of XOSPATA® (gilteritinib) for Regulatory Review in China by the National Medical Products Administration (Press)

• Medtechs adapt to new sales reality amid halt on elective surgeries, hospitals' financial stress (MedtechDive)

• Court’s Construction of the Term “Original New Drug Application” Formerly in Medicaid Rebate Statute Offers Rebate Relief for Some Drugs Approved Under Literature-Based NDAs (FDA Law Blog)
• Court sides with Nevro over Boston Scientific in pain device patent dispute (MedtechDive)
• Part D Redesign: MedPAC Finalizes Recommendations To Congress But COVID-19 Will Get In The Way (Pink Sheet-$)
• On Promoting Off-Label Use II (Drug & Device Law)
• COVID-19 Test Maker Hits 'Nefarious' Co. With TM Suit (Law360)
• Daiichi Says Court Should Decide Drug Patent Fight Venue (Law360-$)
• Pfizer v. J&J Remicade Antitrust Trial Deadlines Extended Due to COVID-19 Pandemic (Big Molecule Watch)
• BASF Corp. v. SNF Holding Co. (Fed. Cir. 2020) (Patent Docs)

• COVID-19: All haemofiltration systems including machines and accessories – serious risks if users don’t follow manufacturer instructions for set-up (MDA/2020/013) (MHRA)

• New China Drug Regulation Legalizes Emergency Approval Mechanism (Pink Sheet-$)

• Health ministry equipped with only two notified labs to test and certify huge quantum of PPE procured in the country (Pharmabiz)
• Supply chain issues hit testing ramp-up: Roche Diagnostics India MD Shravan Subramanyam (Economic Times)